Compare LKFN & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LKFN | PHVS |
|---|---|---|
| Founded | 1872 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 1997 | 2021 |
| Metric | LKFN | PHVS |
|---|---|---|
| Price | $60.30 | $24.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $67.00 | $39.44 |
| AVG Volume (30 Days) | 157.8K | ★ 534.0K |
| Earning Date | 01-23-2026 | 11-12-2025 |
| Dividend Yield | ★ 3.34% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.79 | N/A |
| Revenue | ★ $248,271,000.00 | N/A |
| Revenue This Year | $17.16 | N/A |
| Revenue Next Year | $3.98 | N/A |
| P/E Ratio | $15.81 | ★ N/A |
| Revenue Growth | ★ 2.85 | N/A |
| 52 Week Low | $50.00 | $11.51 |
| 52 Week High | $73.85 | $29.80 |
| Indicator | LKFN | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 57.46 | 48.08 |
| Support Level | $59.00 | $23.61 |
| Resistance Level | $60.56 | $24.63 |
| Average True Range (ATR) | 1.33 | 1.94 |
| MACD | 0.27 | -0.32 |
| Stochastic Oscillator | 87.73 | 16.47 |
Lakeland Financial Corp is a bank holding company. It provides commercial, retail, wealth advisory, and investment management services. It offers a broad line of products and services throughout its Northern and Central Indiana markets. The company provides commercial and consumer banking services, as well as trust and wealth management, brokerage, and treasury management commercial services. It serves a wide variety of industries including, among others, commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and healthcare.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.